{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:42:10Z","timestamp":1773297730277,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","psychiatricnursing.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Psychiatric Nursing"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.apnu.2008.06.007","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T04:29:53Z","timestamp":1232080193000},"page":"261-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Prevalence and Predictors of Metabolic Syndrome Among Patients Attending an Outpatient Clozapine Clinic in Australia"],"prefix":"10.1016","volume":"23","author":[{"given":"Scott","family":"Brunero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Lamont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Fairbrother","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apnu.2008.06.007_bib1","first-page":"39","article-title":"Clozapine: The commitment to patient safety","volume":"60","author":"Alphs","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib2","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.apnu.2008.06.007_bib3","first-page":"81","article-title":"Mortality among homeless people with schizophrenia in Sydney, Australia: A 10 year follow up","volume":"103","author":"Babidge","year":"2001","journal-title":"Acta Psychiatrica Scandanivica"},{"key":"10.1016\/j.apnu.2008.06.007_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00023210-200721020-00003","article-title":"Monitoring the safe use of clozapine","volume":"21","author":"Berk","year":"2007","journal-title":"CNS Drugs"},{"issue":"16","key":"10.1016\/j.apnu.2008.06.007_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/10398560801979222","article-title":"Blue Card: A hand-held health record card for mental health consumers with co-morbid physical health risk","volume":"7","author":"Brunero","year":"2008","journal-title":"Australasian Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.apnu.2008.06.007_bib7","first-page":"1","article-title":"Congruencies in increased mortality rates years of potential life lost, and causes of death among public mental health clients in eight states","volume":"3","author":"Colton","year":"2006","journal-title":"Preventing Chronic Disease"},{"key":"10.1016\/j.apnu.2008.06.007_bib8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","article-title":"Prevalence and correlates of diabetes in national schizophrenic samples","volume":"26","author":"Dixon","year":"2000","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.apnu.2008.06.007_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002018-200629040-00002","article-title":"Long-term treatment with atypical antipsychotics and the risk of weight gain","volume":"29","author":"Gentile","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.apnu.2008.06.007_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.v68n0103","article-title":"Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics. A retrospective chart review","volume":"68","author":"Goethe","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weigh gain, and lipid abnormalities: A five year naturalistic study","volume":"157","author":"Henderson","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10401230590932407","article-title":"Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient","volume":"17","author":"Henderson","year":"2005","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1176\/ps.50.6.827","article-title":"Health and self-care practices of persons with schizophrenia","volume":"50","author":"Holmberg","year":"1999","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.apnu.2008.06.007_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1463-1326.2005.00495.x","article-title":"Association between antipsychotic drugs and diabetes","volume":"8","author":"Holt","year":"2006","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.apnu.2008.06.007_bib15","author":"International Diabetes Federation"},{"key":"10.1016\/j.apnu.2008.06.007_bib16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1192\/apt.11.6.457","article-title":"Physical health in mental illness: Psychiatric shared responsibility","volume":"11","author":"Kohen","year":"2005","journal-title":"Advances in Psychiatric Treatment"},{"key":"10.1016\/j.apnu.2008.06.007_bib18","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.4088\/JCP.v68n1006","article-title":"Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripriprazole versus olanzapine or placebo","volume":"68","author":"L'Italien","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib19","doi-asserted-by":"crossref","first-page":"s67","DOI":"10.5694\/j.1326-5377.2003.tb05311.x","article-title":"Medical co morbidity in schizophrenia","volume":"178","author":"Lambert","year":"2003","journal-title":"Medical Journal of Australia"},{"key":"10.1016\/j.apnu.2008.06.007_bib20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1176\/ajp.2006.163.7.1273","article-title":"Prevalence of the metabolic syndrome among patients receiving clozapine","volume":"163","author":"Lamberti","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1192\/bjp.182.1.31","article-title":"Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980\u20131998","volume":"182","author":"Lawrence","year":"2003","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomised controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.apnu.2008.06.007_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-004-1641-y","article-title":"Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study","volume":"48","author":"Mackin","year":"2005","journal-title":"Diabetlogia"},{"key":"10.1016\/j.apnu.2008.06.007_bib24","doi-asserted-by":"crossref","first-page":"s21","DOI":"10.1192\/bjp.191.50.s21","article-title":"Patient-reported outcomes in schizophrenia","volume":"191","author":"McCabe","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"Mcevoy","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.apnu.2008.06.007_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2005.03.085","article-title":"Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?","author":"Mclaughlin","year":"2005","journal-title":"American Journal of Cardiology"},{"key":"10.1016\/j.apnu.2008.06.007_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00005053-197704000-00002","article-title":"Conditions predisposing to suicide: A review","volume":"164","author":"Miles","year":"1977","journal-title":"Journal of Nervous and Mental Disorders"},{"key":"10.1016\/j.apnu.2008.06.007_bib28","author":"National Suicide Prevention Strategy"},{"key":"10.1016\/j.apnu.2008.06.007_bib29","author":"National Cholesterol Education Program"},{"key":"10.1016\/j.apnu.2008.06.007_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S1092852900026663","article-title":"Metabolic findings from the CATIE trial and their relation to tolerability","volume":"11","author":"Nasrallah","year":"2006","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.apnu.2008.06.007_bib31","first-page":"8","article-title":"Antipsychotic medications: Metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib32","first-page":"20","article-title":"Metabolic considerations in the use of antipsychotic medication: A review of recent evidence","volume":"68","author":"Newcomer","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia","volume":"62","author":"Palmer","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1139\/jpn.0733","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"Journal of Psychiatry Neuroscience"},{"key":"10.1016\/j.apnu.2008.06.007_bib35","author":"Rationale for the New Worldwide Definition of Metabolic Syndrome"},{"key":"10.1016\/j.apnu.2008.06.007_bib36","series-title":"Clinical pharmacogenomics","article-title":"Drug-induced metabolic syndrome (DMS) in psychiatry: A diagnostic need uniquely suited to pharmacogenomics","author":"Ruano","year":"2005"},{"key":"10.1016\/j.apnu.2008.06.007_bib37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1192\/bjp.173.3.270b","article-title":"Sudden death in psychiatric patients","volume":"173","author":"Ruschena","year":"1998","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","article-title":"Impaired fasting glucose tolerance in first episode, drug naive patients with schizophrenia","volume":"160","author":"Ryan","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib39","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia","volume":"64","author":"Saha","year":"2007","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib40","first-page":"14","article-title":"Implementation of monitoring and management guidelines for second generation antipsychotics","volume":"68","author":"Sernyak","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1176\/appi.ajp.162.6.1217","article-title":"Cost effective screening for the metabolic syndrome in patients treated with second generation antipsychotic medications","volume":"162","author":"Straker","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4088\/JCP.v68n0711","article-title":"Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey","volume":"68","author":"Suvisaari","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib43","doi-asserted-by":"crossref","first-page":"s76","DOI":"10.1192\/bjp.184.47.s76","article-title":"Metabolic disturbance in first-episode schizophrenia","volume":"184","author":"Thakore","year":"2004","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.apnu.2008.06.007_bib44","doi-asserted-by":"crossref","first-page":"s115","DOI":"10.1016\/j.euroneuro.2007.02.003","article-title":"The stable patient with schizophrenia\u2014from antipsychotic effectiveness to adherence","volume":"17","author":"Thomas","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.apnu.2008.06.007_bib45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2850.2006.01026.x","article-title":"The metabolic syndrome and schizophrenia: The latest evidence and nursing guidelines for management","volume":"13","author":"Usher","year":"2006","journal-title":"Journal of Psychiatric and Mental Health Nursing"},{"key":"10.1016\/j.apnu.2008.06.007_bib46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2004.11.007","article-title":"Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation","volume":"76","author":"Volvaka","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.apnu.2008.06.007_bib47","series-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus","first-page":"1","author":"World Health Organization","year":"1999"},{"key":"10.1016\/j.apnu.2008.06.007_bib48","article-title":"Medicolegal considerations in the treatment of psychosis with second generation antipsychotics","volume":"21","author":"Wirshing","year":"2004","journal-title":"Psychiatric Times"},{"key":"10.1016\/j.apnu.2008.06.007_bib49","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ps.2007.58.4.544","article-title":"Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six month diet and physical activity program","volume":"58","author":"Wu","year":"2007","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.apnu.2008.06.007_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jad.2006.08.009","article-title":"Atypical antipsychotics related metabolic syndrome in bipolar patients","volume":"98","author":"Yumru","year":"2007","journal-title":"Journal of Affective Disorders"}],"container-title":["Archives of Psychiatric Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883941708001374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883941708001374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:19Z","timestamp":1760123659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883941708001374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0883941708001374"],"URL":"https:\/\/doi.org\/10.1016\/j.apnu.2008.06.007","relation":{},"ISSN":["0883-9417"],"issn-type":[{"value":"0883-9417","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and Predictors of Metabolic Syndrome Among Patients Attending an Outpatient Clozapine Clinic in Australia","name":"articletitle","label":"Article Title"},{"value":"Archives of Psychiatric Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apnu.2008.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2009 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}